Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis.

Luke Evan BarryGrainne E CrealeyPaul CockwellStephen J EllimanMatthew D GriffinAlexander Peter MaxwellTimothy O'BrienNorberto PericoCiaran O'Neill

Published in: PloS one (2022)

The evidence base regarding the effectiveness of MSC therapy continues to evolve. The potential for these therapies to reverse kidney damage would see large improvements in their cost-effectiveness as would targeting such therapies at younger patients and/or those for whom SGLT2i is contra-indicated.

Keyphrases

cell therapy
end stage renal disease
stem cells
bone marrow
ejection fraction
newly diagnosed
healthcare
randomized controlled trial
type diabetes
chronic kidney disease
systematic review
palliative care
prognostic factors
peritoneal dialysis
oxidative stress
chronic pain
patient reported
climate change